Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, and Mundipharma China Pharmaceutical, the leading pain management market, today jointly announced that Akynzeo ® has been approved by the National Medical Products Administration (NMPA) for the therapy of chemotherapy-induced nausea and vomiting (CINV) in China.
Mundipharma China Pharmaceutical has exclusive marketing, promotion and sales rights under the terms of the agreement for Akynzeo ®’s oral formulation in China. Helsinn will be accountable for providing Mundipharma with the medication and co-detailing the Shanghai product while maintaining all global development privileges, including clinical development operations.
Riccardo Braglia, Vice President and CEO of the Helsinn Group, commented: “Despite the availability of several antiemetics, lack of control of CINV is a problem. We are pleased that Akynzeo ®, which targets two CINV critical pathways in one dose, will assist patients and their relatives in China as well.
Peter Wang, Chief Executive Officer of Mundipharma Pharmaceutical Greater China commented: “Today’s announcement will be welcomed by Chinese cancer patients who undergo chemotherapy while fighting against CINV and caregivers.
About Akynzeo® in China
Akynzeo ® capsule (300 mg netupitant/0.5 mg palonosetron) was endorsed in China on 2 August 2019 and is stated in adolescents for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic chemotherapy for cancer and the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy for cancer.
About the Helsinn Group
Helsinn is a privately held pharmaceutical group with a wide portfolio of marketed products for cancer care and a solid pipeline for drug development. Helsinn has improved patients ‘ daily life since 1976, guided by key family values of regard, integrity, and quality.
About Mundipharma China Pharmaceutical
Established in 1993, Mundipharma China Pharmaceutical has been devoted to the organic growth of the pain segment in China for centuries. “Bringing more to life” is our aspiration; our social obligations are to care for life and serve society. Our DNAs include innovation, patient-centeredness, and entrepreneurship.